Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-authorization, Observational Study to Assess the Evolution in the Normal Clinical Practise of Patients With Recent Diagnosis of Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML), Depending on the Time of Active Treatment Initiated

NCT02085798 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02085798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02085798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-authorization, Observational Study to Assess the Evolution in the Normal Clinical Practise of Patients With Recent Diagnosis of Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML), Depending on the Time of Active Treatment Initiated
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
December 17, 2012
Completion date
December 14, 2018
Enrollment
503 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myelomonocytic, chronic, myelodysplastic syndrome